What Changed Before the Scale Stopped Moving?

Six things could have changed. Not one — six, and none of them leaves a mark on a weight:

1. The dose — what it is, and the exact date it last went up, went down, or held.
2. Appetite and meal completion — whether meals are being finished, and when that started being true.
3. Symptoms and their start dates — not whether nausea or fatigue happened, but the day each one began. (What to write down in the first week after a dose increase covers this one in detail.)
4. Missed doses and pharmacy gaps — the refill that came late, the injection taken off schedule, the supply problem that resolved.
5. Interruptions — illness, travel, a week of unusual days, a routine that came apart and went back together.
6. How the weigh-in was taken — same time of day, same conditions, same kind of day, or not.

That is the whole answer. A scale is a measurement, not a record. It reports where things are today and discards how they got there — so the six sit outside it, and only a record holds them. The GLP-1 Dose & Symptom Record is built around exactly these six, dated.

The rest of this article is about why they matter, and why they are hard to recover after the fact.

Why the six matter: different situations look identical on the scale

Several situations produce the same unmoving number, and they are not the same situation.

The total may be holding still while its parts move. Body weight is a single number covering many things at once. A total can stay the same while what is inside it changes, and the total does not report which.

Intake may have moved without a decision being made. A weight does not record what was eaten. A change in portions or in meals finished leaves no mark on the number — only on a record of meals.

Energy needs may have changed. Weight reduction is accompanied by measurable adaptations in energy expenditure — documented in weight loss generally (Müller & Bosy-Westphal, 2013) and observed during GLP-1-assisted weight loss as well (Gorgojo-Martínez et al., 2023). The routine that produced steady loss earlier may not produce the same result at a lower weight.

Or something in the treatment itself changed — time at a dose, a pause, a missed week, a switch. That one belongs to you and your prescriber, and this article does not go there.

Different situations. One identical number. The six details above are what separate them, and none of them are medical or difficult to notice while they are happening.

A plateau is expected, and expected is not the same as explained

Weight loss on these medications is not a straight line. In the STEP 5 trial of semaglutide 2.4 mg, mean weight loss leveled off at roughly week 60 and then held at about 15.2% through 104 weeks of continued treatment (Garvey et al., 2022).

Knowing this is common tells you that your experience is normal. It does not tell you anything about yours. The trial describes an average across hundreds of people. You are one person, with one sequence of doses, weeks, meals, symptoms, and interruptions. An average is a description of a population, not a forecast for anyone inside it.

Memory does not decline to answer — it answers wrong

Blank memory announces itself, and you know to go looking. The harder problem is that reconstruction feels like recall.

Autobiographical memory is constructed at the moment of remembering rather than replayed from storage, and what gets constructed is shaped by the goals and beliefs a person holds at the time of recall (Conway & Pleydell-Pearce, 2000). Which means a working theory arriving at the question first will be met with a version that supports it. The version arrives with confidence attached, and the confidence is not evidence. That failure is the whole subject of the companion essay, Why Can't You Remember What Week the Nausea Started?

None of the six is hard to notice while it is happening. All of it is hard to recover afterward — unless it was written down at the time, while it was still ordinary.

What a written record gives back

Eight weeks of dated notes will not tell you why the number stopped moving. Nothing can tell you that from the outside, and anything claiming otherwise is guessing at you.

What it does is make the question answerable instead of unanswerable:

• A level stretch can be laid beside a dose change, or beside an appetite change — and the two stop being the same story.
• A pattern that happened before becomes visible as a pattern that happened before, along with how long it lasted last time.
• A number that looked unmoving across two weigh-ins may read differently across eight dated ones.
• And an appointment changes shape. "It's been rough lately" and "it started nine days after the dose went up, lasted about two weeks, and hasn't come back" are not the same sentence, and they do not produce the same conversation.

The scale does not preserve the events that came before it. Only a record does that — and only if it was written while they were still ordinary. The GLP-1 Dose & Symptom Record is built for the six. If a different question is the one you actually have, start here or browse the GLP-1 Observation Records.

Sources

Conway, M. A., & Pleydell-Pearce, C. W. (2000). The construction of autobiographical memories in the self-memory system. Psychological Review, 107(2), 261–288.

Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083–2091.

Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á. (2023). Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine, 12(1), 145.

Müller, M. J., & Bosy-Westphal, A. (2013). Adaptive thermogenesis with weight loss in humans. Obesity, 21(2), 218–228.

Disclaimer

This article is educational and is about observation and recordkeeping. It is not medical advice, and it does not diagnose or treat any condition. Nothing here should be used to start, stop, change, or delay any treatment. Decisions about medication, dosing, and care belong to you and your prescriber. If something you are experiencing concerns you, or if symptoms are severe, worsening, or persistent, contact a qualified healthcare professional. Sacred Books publishes records for documenting what you observe. It does not interpret those observations for you.

Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are registered trademarks of their respective manufacturers. Sacred Books, LLC is not affiliated with, sponsored by, or endorsed by these manufacturers.